

Improving Biomarker Driven Precision Therapy in NSCLC: Uncovering ALK in Clinical Practice: Physician, Pharmacist, and Patient Perspectives

May 10, 2022 | 5:00 – 6:00 pm

Live Online: <https://cme.bu.edu/NSCLCpart4>

Faculty

David Hughes, PharmD, BCOP

Jasmine Patel, PharmD

Umit Tapan, MD

Learning Objectives

At the completion of this activity, pharmacists will be able to:

1. Identify operational and clinical barriers that may interfere with optimal biomarker based testing and develop initiatives to offset these barriers
2. Describe first and subsequent line targeted treatment approaches for adult patients with metastatic ALK-mutated NSCLC
3. Discuss strategies to mitigate adverse effects of treatment to improve long-term survival and quality of life for patients with ALK-mutated NSCLC

CONTINUING EDUCATION CREDITS



The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an application-based educational activity. Pharmacists will receive 1.0 contact hours (0.10 CEUS) for the educational activity. No partial credit is available.

UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-22-037-L01-P

PROGRAM EVALUATION

Participants will have the opportunity to evaluate the educational session and speaker and to identify educational needs.

REQUIREMENTS FOR CE CREDIT

A program evaluation must be completed at www.uriparmacypd.org within 60 days of the live program date (5/10/2022) in order to receive CE credit. Please refer to the evaluation instructions that follow for completing program evaluations.

FACULTY DISCLOSURE

Dr. Patel's organization has received grant funding from Pfizer Inc. Neither Dr. Hughes nor Dr. Tapan have relevant financial relationships to disclose.

FUNDING

This program is supported by an educational grant from Pfizer Inc.

Instructions for Completing a Program Evaluation and Earning CPE credit (Pharmacists)

1. Go to the University of Rhode Island College of Pharmacy Continuing Professional Development Learning Management System located at www.uripharmacypcd.org and create an account using your email address and professional license number.* Enter all of the required account information. Click the “Update Account” button at the bottom of the page to save the account information.
2. Complete the program evaluation. **Evaluations must be completed within 60 days of the program.**
 - Log onto www.uripharmacypcd.org
 - Select Complete Live Activity Post-Test/Evaluations and select the program date and title of the activity (see below).
 - Enter the program evaluation code and complete program evaluation.
 - Select submit at the bottom of the page.
 - You will receive a confirmation message of evaluation completion and notification that your CE data was reported to the CPE Monitor.

5/10/2022 Live Webinar, “Improving Biomarker Driven Precision Therapy in NSCLC: Uncovering ALK in Clinical Practice: Physician, Pharmacist, and Patient Perspectives”

Evaluation access code (code is case sensitive): BDPT65

Please note: ACPE will only accept CPE data that is reported by providers within 60 days of a live program or upon completing an enduring activity. CPE data is reported immediately to the CPE Monitor upon your completion of this evaluation although it may take 48-72 hours to appear in your CPE Monitor profile. You will be notified of any problems transmitting your participant data via email. Most transmission problems are related to errors in transcribing date of birth and/or NABP ID number. It is strongly recommended that you check your profile in the CPE Monitor to verify your participation in this program has been reported. CPE statements can be printed from your CPE Monitor account. **CPE Monitor will reject CE data submitted after 60 days.**

*Your pharmacy license number, date of birth and NABP ID number are required to create an account in the URI CPD online registration and evaluation system in order to report participant data to the CPE Monitor. Pharmacy license numbers will not be used for any other purpose.